SA 9.4 Can we de-escalate immunotherapy and chemotherapy in TNBC? von Bonnefoi, H.

Volltext

A review of PARP inhibitors: from bench to bedside von Underhill, C., Toulmonde, M., Bonnefoi, H.

Volltext

A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1) von Bonnefoi, H., Grellety, T., Tredan, O., Saghatchian, M., Dalenc, F., Mailliez, A., L'Haridon, T., Cottu, P., Abadie-Lacourtoisie, S., You, B., Mousseau, M., Dauba, J., Del Piano, F., Desmoulins, I., Coussy, F., Madranges, N., Grenier, J., Bidard, F.C., Proudhon, C., MacGrogan, G., Orsini, C., Pulido, M., Gonçalves, A.

Volltext

Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer von Mosele, F., Stefanovska, B., Lusque, A., Tran Dien, A., Garberis, I., Droin, N., Le Tourneau, C., Sablin, M.-P., Lacroix, L., Enrico, D., Miran, I., Jovelet, C., Bièche, I., Soria, J.-C., Bertucci, F., Bonnefoi, H., Campone, M., Dalenc, F., Bachelot, T., Jacquet, A., Jimenez, M., André, F.

Volltext

Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-st... von Bonnefoi, H., Litière, S., Piccart, M., MacGrogan, G., Fumoleau, P., Brain, E., Petit, T., Rouanet, P., Jassem, J., Moldovan, C., Bodmer, A., Zaman, K., Cufer, T., Campone, M., Luporsi, E., Malmström, P., Werutsky, G., Bogaerts, J., Bergh, J., Cameron, D.A.

Volltext

206 What I Need to Know in the Clinic von Bonnefoi, H

Volltext

Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006 von Kaufmann, M., von Minckwitz, G., Bear, H.D., Buzdar, A., McGale, P., Bonnefoi, H., Colleoni, M., Denkert, C., Eiermann, W., Jackesz, R., Makris, A., Miller, W., Pierga, J.-Y., Semiglazov, V., Schneeweiss, A., Souchon, R., Stearns, V., Untch, M., Loibl, S.

Volltext

A gene signature to predict high tumor-infiltrating lymphocytes after neoadjuvant chemotherapy and outcome in patients with triple-negative breast cancer von Criscitiello, C., Bayar, M.A., Curigliano, G., Symmans, F.W., Desmedt, C., Bonnefoi, H., Sinn, B., Pruneri, G., Vicier, C., Pierga, J.Y., Denkert, C., Loibl, S., Sotiriou, C., Michiels, S., André, F.

Volltext

Neoadjuvant treatment with docetaxel plus lapatinib, trastuzumab, or both followed by an anthracycline-based chemotherapy in HER2-positive breast cancer: results of the randomised... von Bonnefoi, H., Jacot, W., Saghatchian, M., Moldovan, C., Venat-Bouvet, L., Zaman, K., Matos, E., Petit, T., Bodmer, A., Quenel-Tueux, N., Chakiba, C., Vuylsteke, P., Jerusalem, G., Brain, E., Tredan, O., Messina, C.G.M., Slaets, L., Cameron, D.

Volltext

Genomic characterisation of hormone receptor-positive breast cancer arising in very young women von Luen, S.J., Viale, G., Nik-Zainal, S., Savas, P., Kammler, R., Dell’Orto, P., Biasi, O., Degasperi, A., Brown, L.C., Láng, I., MacGrogan, G., Tondini, C., Bellet, M., Villa, F., Bernardo, A., Ciruelos, E., Karlsson, P., Neven, P., Climent, M., Müller, B., Jochum, W., Bonnefoi, H., Martino, S., Davidson, N.E., Geyer, C., Chia, S.K., Ingle, J.N., Coleman, R., Solbach, C., Thürlimann, B., Colleoni, M., Coates, A.S., Goldhirsch, A., Fleming, G.F., Francis, P.A., Speed, T.P., Regan, M.M., Loi, S.

Volltext

A clinical case of invasive lobular breast carcinoma with ERBB2 and CDH1 mutations presenting a dramatic response to anti-HER2-directed therapy von Grellety, T., Soubeyran, I., Robert, J., Bonnefoi, H., Italiano, A.

Volltext

De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 von Curigliano, G, Burstein, H J, Winer, E P, Gnant, M, Dubsky, P, Loibl, S, Colleoni, M, Regan, M M, Piccart-Gebhart, M, Senn, H -J, Thürlimann, B, André, F, Baselga, J, Bergh, J, Bonnefoi, H, Brucker, S Y, Cardoso, F, Carey, L, Ciruelos, E, Cuzick, J, Denkert, C, Di Leo, A, Ejlertsen, B, Francis, P, Galimberti, V, Garber, J, Gulluoglu, B, Goodwin, P, Harbeck, N, Hayes, D F, Huang, C -S, Huober, J, Khaled, H, Jassem, J, Jiang, Z, Karlsson, P, Morrow, M, Orecchia, R, Osborne, K C, Pagani, O, Partridge, A H, Pritchard, K, Ro, J, Rutgers, E J T, Sedlmayer, F, Semiglazov, V, Shao, Z, Smith, I, Toi, M, Tutt, A, Viale, G, Watanabe, T, Whelan, T J, Xu, B

Volltext

Tumour size is the only predictive factor of distant recurrence after pathological complete response to neoadjuvant chemotherapy in patients with large operable or locally advanced... von Fei, F, Messina, C, Slaets, L, Chakiba, C, Cameron, D, Bogaerts, J, Bonnefoi, H

Volltext

START: A randomized phase II study in patients with triple negative, androgen receptor positive locally recurrent (unresectable) or metastatic breast cancer treated with darolutami... von Bonnefoi, H., Levy, C., MacGrogan, G., Grellety, T., Asselain, B., Pulido, M., Everhard, S., Lemonnier, J., Gonçalves, A.

Volltext

Symptoms of endocrine treatment and outcome in the BIG 1-98 study von Huober, J., Cole, B. F., Rabaglio, M., Giobbie-Hurder, A., Wu, J., Ejlertsen, B., Bonnefoi, H., Forbes, J. F., Neven, P., Láng, I., Smith, I., Wardley, A., Price, K. N., Goldhirsch, A., Coates, A. S., Colleoni, M., Gelber, R. D., Thürlimann, B.

Volltext

Pertuzumab (P) + trastuzumab (T) with or without chemotherapy both followed by T-DM1 in case of progression in patients with HER2-positive metastatic breast cancer (MBC) - The PERN... von Huober, J., Ribi, K., Weder, P., Li, Q., Vanlemmens, L., Gerard, M.-A., Lemonnier, J., Thürlimann, B., Boven, E., Bonnefoi, H.

Volltext

Final Results of a Randomized Phase III Trial Comparing Cyclophosphamide, Epirubicin, and Fluorouracil With a Dose-Intensified Epirubicin and Cyclophosphamide + Filgrastim as Neoad... von Therasse, P, Mauriac, L, Welnicka-Jaskiewicz, M, Bruning, P, Cufer, T, Bonnefoi, H, Tomiak, E, Pritchard, K I, Hamilton, A, Piccart, M J

Volltext

Endocrine-responsive breast cancer special types: who cares? von Bonnefoi, H., MacGrogan, G.

Volltext

PERNETTA: A non-comparative randomized open label phase II trial of pertuzumab (P) + trastuzumab (T) with or without chemotherapy both followed by T-DM1 in case of progression, in... von Huober, J., Weder, P., Veyret, C., Thürlimann, B., Xyrafas, A., Vanlemmens, L., Guiu, S., Brain, E., Grenier, J., Dalenc, F., Levy, C., Savoye, A.M., Müller, A., Membrez-Antonioli, V., Gerard, M.A., Lemonnier, J., Hawle, H., Boven, E., Bonnefoi, H.

Volltext

An immunological signature to predict outcome in patients with triple-negative breast cancer with residual disease after neoadjuvant chemotherapy von Blaye, C., Darbo, É., Debled, M., Brouste, V., Vélasco, V., Pinard, C., Larmonier, N., Pellegrin, I., Tarricone, A., Arnedos, M., Commeny, J., Bonnefoi, H., Larmonier, C., MacGrogan, G.

Volltext